

Jan Beyer-Westendorf

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5738109/publications.pdf>

Version: 2024-02-01

191
papers

11,017
citations

57681

46
h-index

36203

101
g-index

199
all docs

199
docs citations

199
times ranked

9751
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacokinetics of Direct Oral Anticoagulants in Emergency Situations: Results of the Prospective Observational RADOA-Registry. <i>Thrombosis and Haemostasis</i> , 2022, 122, 552-559.	1.8	8
2	Estimating Bleeding Risk in Patients with Cancer-Associated Thrombosis: Evaluation of Existing Risk Scores and Development of a New Risk Score. <i>Thrombosis and Haemostasis</i> , 2022, 122, 818-829.	1.8	23
3	Hematoma Expansion and Clinical Outcomes in Patients With Factor-Xa Inhibitor-Related Atraumatic Intracerebral Hemorrhage Treated Within the ANNEXA-4 Trial Versus Real-World Usual Care. <i>Stroke</i> , 2022, 53, 532-543.	1.0	25
4	Development and validation of an analytical method for the determination of direct oral anticoagulants (DOAC) and the direct thrombin-inhibitor argatroban by HPLC-MS/MS. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 53, 777-787.	1.0	7
5	Point of care coagulation management in anesthesiology and critical care. <i>Minerva Anestesiologica</i> , 2022, 88, .	0.6	6
6	Rivaroxaban for the treatment of noncirrhotic splanchnic vein thrombosis: an interventional prospective cohort study. <i>Blood Advances</i> , 2022, 6, 3569-3578.	2.5	19
7	Intracranial bleeding under vitamin K antagonists or direct oral anticoagulants: results of the RADOA registry. <i>Neurological Research and Practice</i> , 2022, 4, 16.	1.0	3
8	Effectiveness and safety of edoxaban therapy in daily-care patients with atrial fibrillation. Results from the DRESDEN NOAC REGISTRY. <i>Thrombosis Research</i> , 2022, 215, 37-40.	0.8	3
9	Anticoagulant therapy for splanchnic vein thrombosis: an individual patient data meta-analysis. <i>Blood Advances</i> , 2022, 6, 4516-4523.	2.5	16
10	Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis. <i>Critical Care</i> , 2022, 26, .	2.5	23
11	Effectiveness and safety of rivaroxaban versus warfarin in obese patients with acute venous thromboembolism: analysis of electronic health record data. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 349-358.	1.0	19
12	Treatment of cancer-associated thrombosis: The evolution of anticoagulant choice and clinical insights into practical management. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103125.	2.0	11
13	Clinical history of cancer-associated splanchnic vein thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 983-991.	1.9	12
14	Survival and quality of life after early discharge in low-risk pulmonary embolism. <i>European Respiratory Journal</i> , 2021, 57, 2002368.	3.1	17
15	Anticoagulation Treatment in Cancer-Associated Venous Thromboembolism: Assessment of Patient Preferences Using a Discrete Choice Experiment (COSIMO Study). <i>Thrombosis and Haemostasis</i> , 2021, 121, 206-215.	1.8	12
16	Heavy menstrual bleeding in women on anticoagulant treatment for venous thromboembolism: Comparison of high- and low-dose rivaroxaban with aspirin. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, 308-313.	1.0	6
17	Hormonal Contraception. Guideline of the DGGG, OEGGG and SCGG (S3 Level, AWMF Registry Number) Tj ETQq1 1 0,784314,rgBT /Ove	0.8	13
18	Direct Oral Anticoagulants in Atrial Fibrillation: Practical Considerations and Remaining Issues. <i>Hamostaseologie</i> , 2021, 41, 035-041.	0.9	1

#	ARTICLE	IF	CITATIONS
19	Restart of Anticoagulant Therapy and Risk of Thrombosis, Rebleeding, and Death after Factor Xa Inhibitor Reversal in Major Bleeding Patients. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1097-1106.	1.8	14
20	Checkpoint inhibitors and thrombosis: what's up?. <i>Blood</i> , 2021, 137, 1569-1570.	0.6	1
21	Definition of haemostatic effectiveness in interventions used to treat major bleeding: Communication from the ISTH SSC Subcommittee on Control of Anticoagulation. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1112-1115.	1.9	8
22	Venous Thromboembolism Therapy with Apixaban in Daily Care Patients: Results from the Dresden NOAC Registry. <i>TH Open</i> , 2021, 05, e143-e151.	0.7	1
23	SARS-CoV-2 Vaccine and Thrombosis: An Expert Consensus on Vaccine-Induced Immune Thrombotic Thrombocytopenia. <i>Thrombosis and Haemostasis</i> , 2021, 121, 982-991.	1.8	50
24	Homoarginine and methylarginines independently predict long-term outcome in patients presenting with suspicion of venous thromboembolism. <i>Scientific Reports</i> , 2021, 11, 9569.	1.6	4
25	Reproductive issues in women on direct oral anticoagulants. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12512.	1.0	9
26	5-year outcomes from rivaroxaban therapy in atrial fibrillation: Results from the Dresden NOAC Registry. <i>Thrombosis Research</i> , 2021, 202, 24-30.	0.8	7
27	The Importance of Appropriate Dosing of Nonvitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation. <i>TH Open</i> , 2021, 05, e353-e362.	0.7	5
28	Secondary Immune Thrombocytopenia (ITP) Associated with ChAdOx1 Covid-19 Vaccination – A Case Report. <i>TH Open</i> , 2021, 05, e315-e318.	0.7	11
29	Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1874-1882.	1.9	122
30	Quality of life in patients with pulmonary embolism treated with edoxaban versus warfarin. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12566.	1.0	3
31	Every 6 Seconds in Europe. <i>Thrombosis Research</i> , 2021, , .	0.8	1
32	Detection of Direct Oral Anticoagulants in Patient Urine Samples by Prototype and Commercial Test Strips for DOACs – A Systematic Review and Meta-analysis. <i>TH Open</i> , 2021, 05, e438-e448.	0.7	7
33	The prognostic value of respiratory symptoms and performance status in ambulatory cancer patients and unsuspected pulmonary embolism; analysis of an international, prospective, observational cohort study. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2791-2800.	1.9	7
34	Patient-reported outcomes associated with changing to rivaroxaban for the treatment of cancer-associated venous thromboembolism – The COSIMO study. <i>Thrombosis Research</i> , 2021, 206, 1-4.	0.8	10
35	Edoxaban dosing patterns in real life practice – Results from the DRESDEN NOAC REGISTRY. <i>Thrombosis Update</i> , 2021, 5, 100070.	0.4	1
36	Rationale and design of XARENO: XA inhibition in RENal patients with non-valvular atrial fibrillation. <i>Observational registry. Kardiologia Polska</i> , 2021, 79, 1265-1267.	0.3	4

#	ARTICLE	IF	CITATIONS
37	Cancer-associated Thromboses – Patient-reported Outcomes With Rivaroxaban (COSIMO) – Baseline characteristics and clinical outcomes. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12604.	1.0	3
38	First trimester anticoagulant exposure and adverse pregnancy outcomes in women with preconception venous thromboembolism: a nationwide cohort study. <i>American Journal of Medicine</i> , 2021, . .	0.6	4
39	Long-term VTE treatment with rivaroxaban: Results from the DRESDEN NOAC REGISTRY. <i>Thrombosis Research</i> , 2021, 208, 181-189.	0.8	0
40	Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre single-arm clinical trial. <i>European Heart Journal</i> , 2020, 41, 509-518.	1.0	106
41	Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. <i>Lancet Haematology</i> , 2020, 7, e18-e27.	2.2	173
42	Accuracy of a Rapid Diagnostic Test for the Presence of Direct Oral Factor Xa or Thrombin Inhibitors in Urine – A Multicenter Trial. <i>Thrombosis and Haemostasis</i> , 2020, 120, 132-140.	1.8	30
43	Rivaroxaban Versus Warfarin for Management of Obese African Americans With Non-Valvular Atrial Fibrillation or Venous Thromboembolism: A Retrospective Cohort Analysis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962095491.	0.7	3
44	Safety of direct oral anticoagulant exposure during pregnancy: a retrospective cohort study. <i>Lancet Haematology</i> , 2020, 7, e884-e891.	2.2	38
45	Definition of major bleeding: Prognostic classification. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2852-2860.	1.9	21
46	Rates, management and outcome of bleeding complications during edoxaban therapy in daily care – results from the DRESDEN NOAC REGISTRY. <i>Thrombosis Research</i> , 2020, 190, 91-98.	0.8	6
47	Anticoagulation with direct factor Xa inhibitors in transplant recipients: Results from the DRESDEN NOAC REGISTRY (NCT01588119). <i>Thrombosis Research</i> , 2020, 191, 50-55.	0.8	2
48	Systematic Literature Review of Randomized Trials Comparing Antithrombotic Therapy Following Revascularization Procedures in Patients With Peripheral Artery Disease. <i>Angiology</i> , 2020, 71, 773-790.	0.8	1
49	Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 267-277.	1.0	54
50	Mortality in patients with intracerebral hemorrhage associated with antiplatelet agents, oral anticoagulants or no antithrombotic therapy. <i>European Journal of Internal Medicine</i> , 2020, 75, 35-43.	1.0	17
51	Effectiveness and safety of rivaroxaban versus warfarin in obese nonvalvular atrial fibrillation patients: analysis of electronic health record data. <i>Current Medical Research and Opinion</i> , 2020, 36, 1081-1088.	0.9	29
52	Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein – phase 3 dose-response evaluation. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1672-1685.	1.9	52
53	Anticoagulant therapy for splanchnic vein thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1562-1568.	1.9	60
54	Severe Hemorrhage Associated With Oral Anticoagulants. <i>Deutsches Arzteblatt International</i> , 2020, 117, 312-319.	0.6	12

#	ARTICLE	IF	CITATIONS
55	Hokusai post-PE study: a follow-up study on long-term outcomes of pulmonary embolism in patients treated with edoxaban vs warfarin. , 2020, , .		0
56	Reply: Method agreement analysis and interobserver reliability of the ISTH proposed definitions for effective hemostasis in the management of major bleeding: Methodological issues. Journal of Thrombosis and Haemostasis, 2019, 17, 1398-1399.	1.9	0
57	Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies. Lancet Haematology, the, 2019, 6, e500-e509.	2.2	51
58	2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncology, The, 2019, 20, e566-e581.	5.1	458
59	DOACS in women: pros and cons. Thrombosis Research, 2019, 181, S19-S22.	0.8	11
60	Method agreement analysis and interobserver reliability of the ISTH proposed definitions for effective hemostasis in management of major bleeding. Journal of Thrombosis and Haemostasis, 2019, 17, 499-506.	1.9	6
61	Treatment and Long-Term Clinical Outcomes of Incidental Pulmonary Embolism in Patients With Cancer: An International Prospective Cohort Study. Journal of Clinical Oncology, 2019, 37, 1713-1720.	0.8	90
62	Effectiveness and safety of rivaroxaban and warfarin for prevention of major adverse cardiovascular or limb events in patients with non-atrial fibrillation and type 2 diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 2107-2114.	2.2	29
63	Evaluation of unmet clinical needs in prophylaxis and treatment of venous thromboembolism in high-risk patient groups: cancer and critically ill. Thrombosis Journal, 2019, 17, 6.	0.9	15
64	International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER). Thrombosis Journal, 2019, 17, 7.	0.9	9
65	Exposure to vitamin k antagonists and kidney function decline in patients with atrial fibrillation and chronic kidney disease. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 207-216.	1.0	20
66	Extended anticoagulant therapy in venous thromboembolism: a balanced, fractional factorial, clinical vignette-based study. Haematologica, 2019, 104, e474-e477.	1.7	1
67	Non-vitamin K Antagonist Oral Anticoagulants (NOAC) as an Alternative Treatment Option in Tumor-Related Venous Thromboembolism. Deutsches Arzteblatt International, 2019, 116, 31-38.	0.6	14
68	Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. New England Journal of Medicine, 2019, 380, 1326-1335.	13.9	687
69	Determinants of the Quality of Warfarin Control after Venous Thromboembolism and Validation of the SAME-TT2-R2 Score: An Analysis of Hokusai-VTE. Thrombosis and Haemostasis, 2019, 119, 675-684.	1.8	9
70	Longitudinal kidney function trajectories predict major bleeding, hospitalization and death in patients with atrial fibrillation and chronic kidney disease. International Journal of Cardiology, 2019, 282, 47-52.	0.8	5
71	Evaluation of unmet clinical needs in prophylaxis and treatment of venous thromboembolism in at-risk patient groups: pregnancy, elderly and obese patients. Thrombosis Journal, 2019, 17, 24.	0.9	21
72	The Efficacy and Safety of Andexanet Alfa in Patients With Acute Gastrointestinal Bleeding While Taking Factor Xa Inhibitors: An ANNEXA-4 Sub-Analysis. American Journal of Gastroenterology, 2019, 114, S332-S333.	0.2	4

#	ARTICLE	IF	CITATIONS
73	Impact of Prolonged Anticoagulation with Rivaroxaban on Provoked Venous Thromboembolism Recurrence: IMPROVE-VTE. <i>American Journal of Medicine</i> , 2019, 132, 498-504.	0.6	4
74	Incomplete echocardiographic recovery at 6 months predicts long-term sequelae after intermediate-risk pulmonary embolism. A post-hoc analysis of the Pulmonary Embolism Thrombolysis (PEITHO) trial. <i>Clinical Research in Cardiology</i> , 2019, 108, 772-778.	1.5	44
75	Comparative risk of major bleeding with rivaroxaban and warfarin: Population-based cohort study of unprovoked venous thromboembolism. <i>European Journal of Haematology</i> , 2019, 102, 143-149.	1.1	6
76	Patient Preferences Regarding Anticoagulation Therapy in Patients with Cancer Having a VTE Event - a Discrete Choice Experiment in the Cosimo Study. <i>Blood</i> , 2019, 134, 2159-2159.	0.6	14
77	In Reply. <i>Deutsches Arzteblatt International</i> , 2019, 116, 420-421.	0.6	0
78	Baseline Characteristics and Clinical Outcomes from the Cancer Associated Thrombosis - Patient Reported Outcomes with Rivaroxaban (COSIMO) Trial. <i>Blood</i> , 2019, 134, 2161-2161.	0.6	2
79	Patterns of VTE Treatment with Noac in Cancer Patients - Results of the Prospective Dresden Noac Registry (NCT01588119). <i>Blood</i> , 2019, 134, 3667-3667.	0.6	0
80	Postthrombotic Syndrome in Patients Treated With Rivaroxaban or Warfarin for Venous Thromboembolism. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 575-582.	0.7	18
81	Use of Direct Oral Anticoagulants in Patients with Cancer: Practical Considerations for the Management of Patients with Nausea or Vomiting. <i>Oncologist</i> , 2018, 23, 822-839.	1.9	24
82	Effectiveness and safety of outpatient rivaroxaban versus warfarin for treatment of venous thromboembolism in patients with a known primary hypercoagulable state. <i>Thrombosis Research</i> , 2018, 163, 132-137.	0.8	7
83	What have we learned from real-world NOAC studies in venous thromboembolism treatment?. <i>Thrombosis Research</i> , 2018, 163, 83-91.	0.8	22
84	The CHA2DS2-VASc score strongly correlates with glomerular filtration rate and predicts renal function decline over time in elderly patients with atrial fibrillation and chronic kidney disease. <i>International Journal of Cardiology</i> , 2018, 253, 71-77.	0.8	24
85	Venous thromboembolism therapy with rivaroxaban in daily-care patients: Results from the Dresden NOAC registry. <i>International Journal of Cardiology</i> , 2018, 257, 276-282.	0.8	21
86	Effectiveness and Safety of Rivaroxaban Versus Warfarin in Frail Patients with Venous Thromboembolism. <i>American Journal of Medicine</i> , 2018, 131, 933-938.e1.	0.6	21
87	Gastrointestinal endoscopy in patients receiving novel direct oral anticoagulants: results from the prospective Dresden NOAC registry. <i>Journal of Gastroenterology</i> , 2018, 53, 236-246.	2.3	19
88	American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. <i>Blood Advances</i> , 2018, 2, 3198-3225.	2.5	492
89	Diagnosis and Treatment of Pulmonary Embolism in Challenging Populations. <i>Hamostaseologie</i> , 2018, 38, 87-97.	0.9	2
90	Health-care Cost Impact of Continued Anticoagulation With Rivaroxaban vs Aspirin for Prevention of Recurrent Symptomatic VTE in the EINSTEIN-CHOICE Trial Population. <i>Chest</i> , 2018, 154, 1371-1378.	0.4	4

#	ARTICLE	IF	CITATIONS
91	Risk of bleeding and arterial cardiovascular events in patients with splanchnic vein thrombosis in Denmark: a population-based cohort study. <i>Lancet Haematology</i> , 2018, 5, e441-e449.	2.2	17
92	COSIMO – patients with active cancer changing to rivaroxaban for the treatment and prevention of recurrent venous thromboembolism: a non-interventional study. <i>Thrombosis Journal</i> , 2018, 16, 21.	0.9	20
93	Risk of recurrent venous thromboembolism according to baseline risk factor profiles. <i>Blood Advances</i> , 2018, 2, 788-796.	2.5	71
94	Effectiveness and Safety of Rivaroxaban in Patients With Cancer-Associated Venous Thrombosis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 491-497.	2.3	11
95	Management of major bleeding and outcomes in patients treated with direct oral anticoagulants: results from the START-Event registry. <i>Internal and Emergency Medicine</i> , 2018, 13, 1051-1058.	1.0	25
96	Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1439-1449.	1.8	154
97	Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin. <i>Thrombosis Research</i> , 2018, 168, 121-129.	0.8	11
98	Betrixaban for prevention of venous thromboembolism in acute medically ill patients. <i>European Heart Journal Supplements</i> , 2018, 20, E16-E22.	0.0	7
99	The prothrombin time does not predict the risk of recurrent venous thromboembolism or major bleeding in rivaroxaban-treated patients. <i>Thrombosis Research</i> , 2018, 170, 75-83.	0.8	4
100	Long-Term Outcome of Splanchnic Vein Thrombosis in Cirrhosis. <i>Clinical and Translational Gastroenterology</i> , 2018, 9, e176.	1.3	57
101	Effectiveness and safety of rivaroxaban versus warfarin in patients with unprovoked venous thromboembolism: A propensity-score weighted administrative claims cohort study. <i>Thrombosis Research</i> , 2018, 168, 31-36.	0.8	14
102	Effectiveness and safety of rivaroxaban versus warfarin in patients with provoked venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 339-345.	1.0	10
103	Sex hormones and venous thromboembolism – from contraception to hormone replacement therapy. <i>Vasa - European Journal of Vascular Medicine</i> , 2018, 47, 441-450.	0.6	12
104	NOAC Therapy Is Also Effective and Safe in Patients Older Than 80 Years – Results of the Prospective Dresden NOAC Registry (NCT01588119). <i>Blood</i> , 2018, 132, 422-422.	0.6	0
105	Impact of Prolonged Anticoagulation with Rivaroxaban on Provoked Venous Thromboembolism Recurrence: The Improve-VTE Study. <i>Blood</i> , 2018, 132, 1241-1241.	0.6	3
106	Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial. <i>Lancet Haematology</i> , 2017, 4, e105-e113.	2.2	112
107	The Changing Landscape for Stroke Prevention in AF. <i>Journal of the American College of Cardiology</i> , 2017, 69, 777-785.	1.2	244
108	Management and outcome of gastrointestinal bleeding in patients taking oral anticoagulants or antiplatelet drugs. <i>Journal of Gastroenterology</i> , 2017, 52, 1211-1220.	2.3	31

#	ARTICLE	IF	CITATIONS
109	Rationale, design, and methodology of the observational INSIGHTS-SVT study on the current state of care and outcomes of patients with superficial vein thrombosis. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2017, 5, 553-560.e1.	0.9	6
110	Evaluation of direct oral anticoagulants in superficial-vein thrombosis – Authors' reply. <i>Lancet Haematology</i> , 2017, 4, e254-e255.	2.2	0
111	Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2017, 376, 1211-1222.	13.9	577
112	Impact of Thrombolytic Therapy on the Long-Term Outcome of Intermediate-Risk Pulmonary Embolism. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1536-1544.	1.2	258
113	Major bleeding with vitamin K antagonists or direct oral anticoagulants in real-life. <i>International Journal of Cardiology</i> , 2017, 227, 261-266.	0.8	47
114	Once- versus twice-daily direct oral anticoagulants in non-valvular atrial fibrillation. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1325-1332.	0.9	23
115	Use of Fondaparinux Off-Label or Approved Anticoagulants for Management of Heparin-Induced Thrombocytopenia. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2636-2648.	1.2	53
116	Effectiveness and safety of apixaban therapy in daily-care patients with atrial fibrillation: results from the Dresden NOAC Registry. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 44, 169-178.	1.0	31
117	Response to the Letter by Lucijanic et al., regarding our manuscript – Management and outcome of gastro-intestinal bleeding in patients taking oral anticoagulants or antiplatelet drugs – <i>Journal of Gastroenterology</i> , 2017, 52, 1077-1078.	2.3	0
118	Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials. <i>Thrombosis Research</i> , 2017, 149, 29-37.	0.8	14
119	Rivaroxaban for venous thromboembolism prevention after major orthopedic surgery: translating trial data into routine clinical practice. <i>Orthopedic Research and Reviews</i> , 2017, Volume 9, 1-11.	0.7	4
120	Controversies in venous thromboembolism: to treat or not to treat superficial vein thrombosis. <i>Hematology American Society of Hematology Education Program</i> , 2017, 2017, 223-230.	0.9	22
121	Effectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2016, 115, 939-949.	1.8	114
122	Home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban. <i>Thrombosis and Haemostasis</i> , 2016, 116, 191-197.	1.8	38
123	Letter to the Editor – Gender related aspects of bleeding with rivaroxaban in venous thromboembolism – Potential for pitfalls – <i>Thrombosis Research</i> , 2016, 148, 152-153.	0.8	0
124	Clinical history and antithrombotic treatment of incidentally detected splanchnic vein thrombosis: a multicentre, international prospective registry. <i>Lancet Haematology</i> , 2016, 3, e267-e275.	2.2	55
125	Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use. <i>Blood</i> , 2016, 127, 1417-1425.	0.6	156
126	Management and outcomes of vaginal bleeding and heavy menstrual bleeding in women of reproductive age on direct oral anti-factor Xa inhibitor therapy: a case series. <i>Lancet Haematology</i> , 2016, 3, e480-e488.	2.2	53

#	ARTICLE	IF	CITATIONS
127	Direct Oral Anticoagulants and Women. <i>Seminars in Thrombosis and Hemostasis</i> , 2016, 42, 789-797.	1.5	20
128	Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. <i>New England Journal of Medicine</i> , 2016, 375, 1131-1141.	13.9	692
129	A clinical decision rule and D-dimer testing to rule out upper extremity deep vein thrombosis in high-risk patients. <i>Thrombosis Research</i> , 2016, 148, 59-62.	0.8	15
130	Rivaroxaban real-world evidence: Validating safety and effectiveness in clinical practice. <i>Thrombosis and Haemostasis</i> , 2016, 116, S13-S23.	1.8	39
131	Vaginal bleeding and heavy menstrual bleeding during direct oral anti-Xa inhibitor therapy. <i>Thrombosis and Haemostasis</i> , 2016, 115, 1234-1236.	1.8	32
132	Treatment of venous thromboembolism with rivaroxaban in relation to body weight. <i>Thrombosis and Haemostasis</i> , 2016, 116, 739-746.	1.8	58
133	Pregnancy outcome in patients exposed to direct oral anticoagulants - and the challenge of event reporting. <i>Thrombosis and Haemostasis</i> , 2016, 116, 651-658.	1.8	79
134	Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis. <i>Thrombosis and Haemostasis</i> , 2016, 116, 733-738.	1.8	55
135	Deep Vein Thrombosis – Current Management Strategies. <i>Clinical Medicine Insights Therapeutics</i> , 2016, 8, CMT.S18890.	0.4	2
136	Long-term Anticoagulation With Rivaroxaban for Preventing Recurrent VTE. <i>Chest</i> , 2016, 150, 1059-1068.	0.4	24
137	Independent data about the safety and efficacy of rivaroxaban for prevention of stroke/embolism are needed: Author reply. <i>Europace</i> , 2016, 18, 156.2-158.	0.7	0
138	Low-molecular-weight heparin to prevent recurrent venous thromboembolism in pregnancy: Rationale and design of the Highlow study, a randomised trial of two doses. <i>Thrombosis Research</i> , 2016, 144, 62-68.	0.8	47
139	Standardized use of novel oral anticoagulants plasma level thresholds in a new thrombolysis decision making protocol. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 293-300.	1.0	15
140	Guidance for the management of venous thrombosis in unusual sites. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 129-143.	1.0	87
141	Superficial vein thrombosis treated for 45 days with rivaroxaban versus fondaparinux: rationale and design of the SURPRISE trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 42, 197-204.	1.0	17
142	Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation. <i>Europace</i> , 2016, 18, 1150-1157.	0.7	132
143	Treatment of Acute VTE with Rivaroxaban - Results of the Prospective Dresden Noac Registry (NCT01588119). <i>Blood</i> , 2016, 128, 2618-2618.	0.6	3
144	Rivaroxaban Versus Fondaparinux in the Treatment of Superficial Vein Thrombosis - the Surprise Trial. <i>Blood</i> , 2016, 128, 85-85.	0.6	3

#	ARTICLE	IF	CITATIONS
145	Localization, Management, Resource Consumption and Outcome of Major Gastrointestinal Bleeding in Patients with Direct Oral Anticoagulants, Vka and Antiplatelet Therapy. Blood, 2016, 128, 141-141.	0.6	0
146	Continued commitment to safety: building on the existing rivaroxaban knowledge base: TableÂ1. European Heart Journal Supplements, 2015, 17, D21-D28.	0.0	0
147	Small clots with large impact. Blood, 2015, 126, 926-927.	0.6	2
148	Benefitâ€risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism. Thrombosis and Haemostasis, 2015, 113, 231-246.	1.8	40
149	Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Thrombosis and Haemostasis, 2015, 114, 645-650.	1.8	48
150	Edoxaban for treatment of venous thromboembolism in patients with cancer. Thrombosis and Haemostasis, 2015, 114, 1268-1276.	1.8	79
151	Selection, management, and outcome of vitamin K antagonist-treated patients with atrial fibrillation not switched to novel oral anticoagulants. Thrombosis and Haemostasis, 2015, 114, 1076-1084.	1.8	21
152	Drug persistence with rivaroxaban therapy in atrial fibrillation patients--results from the Dresden non-interventional oral anticoagulation registry. Europace, 2015, 17, 530-538.	0.7	127
153	Development of Recommendations to Continue Anticoagulation with One of the Two Types of Oral Anticoagulants Based on the Identification of Patients' Preference. Seminars in Thrombosis and Hemostasis, 2015, 41, 166-177.	1.5	13
154	Coagulation activation after discontinuation of VTE treatment with different oral anticoagulants and impact on 12-month clinical outcomes. Thrombosis Research, 2015, 136, 261-266.	0.8	5
155	Long-term Clinical Outcomes of Splanchnic Vein Thrombosis. JAMA Internal Medicine, 2015, 175, 1474.	2.6	180
156	Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Thrombosis and Haemostasis, 2015, 113, 1247-1257.	1.8	127
157	Bleeding Risk, Management and Outcome in Patients Receiving Non-VKA Oral Anticoagulants (NOACs). American Journal of Cardiovascular Drugs, 2015, 15, 235-242.	1.0	17
158	Venous thromboembolism prevention and treatment: expanding the rivaroxaban knowledge base with real-life data. European Heart Journal Supplements, 2015, 17, D32-D41.	0.0	10
159	Stroke prevention in atrial fibrillation: evidence from real-life studies: TableÂ1. European Heart Journal Supplements, 2015, 17, D42-D52.	0.0	4
160	Outpatient or inpatient treatment for acute pulmonary embolism: a retrospective cohort study of 439 consecutive patients. Journal of Thrombosis and Thrombolysis, 2015, 40, 26-36.	1.0	14
161	Pattern and Management of Vaginal Bleeding Complications, Especially Hypermenorrhea, with Direct Oral Anticoagulants - Results of the Prospective Dresden Noac Registry (NCT01588119). Blood, 2015, 126, 1131-1131.	0.6	1
162	Pattern and Management of ISTH Major Bleeding Complications with Direct Oral Anticoagulants - Results of the Prospective Dresden Noac Registry (NCT01588119). Blood, 2015, 126, 892-892.	0.6	3

#	ARTICLE	IF	CITATIONS
163	Antithrombotic Treatment of Splanchnic Vein Thrombosis: Results of an International Registry. <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, 099-105.	1.5	39
164	Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry. <i>European Heart Journal</i> , 2014, 35, 1888-1896.	1.0	320
165	Safety of switching from vitamin K antagonists to dabigatran or rivaroxaban in daily care - results from the Dresden NOAC registry. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 908-917.	1.1	51
166	Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment. <i>Thrombosis Journal</i> , 2014, 12, 25.	0.9	55
167	Randomized, Controlled Trial of Ultrasound-Assisted Catheter-Directed Thrombolysis for Acute Intermediate-Risk Pulmonary Embolism. <i>Circulation</i> , 2014, 129, 479-486.	1.6	794
168	Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. <i>Lancet Haematology</i> , 2014, 1, e37-e46.	2.2	244
169	Frequent off-label use of fondaparinux in patients with suspected acute heparin-induced thrombocytopenia (HIT) – findings from the GerHIT multi-centre registry study. <i>Thrombosis Research</i> , 2014, 134, 29-35.	0.8	57
170	Fibrinolysis for Patients with Intermediate-Risk Pulmonary Embolism. <i>New England Journal of Medicine</i> , 2014, 370, 1402-1411.	13.9	1,221
171	Bleeding complications during anticoagulant treatment in patients with cancer. <i>Thrombosis Research</i> , 2014, 133, S49-S55.	0.8	73
172	Safety and Feasibility of a Diagnostic Algorithm Combining Clinical Probability, d-Dimer Testing, and Ultrasonography for Suspected Upper Extremity Deep Venous Thrombosis. <i>Annals of Internal Medicine</i> , 2014, 160, 451.	2.0	62
173	Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. <i>Blood</i> , 2014, 124, 955-962.	0.6	363
174	Centrally Adjudicated Cause of Death during Noac Treatment – Results of the Prospective Dresden Noac Registry (NCT01588119). <i>Blood</i> , 2014, 124, 2876-2876.	0.6	3
175	Drug Persistence with Rivaroxaban Therapy in Atrial Fibrillation Patients Results from the Dresden NOAC registry. <i>Blood</i> , 2014, 124, 4264-4264.	0.6	1
176	Antithrombotic Treatment and Outcomes of Splanchnic Vein Thrombosis in an International Prospective Registry: Results of 2-Year Follow-up. <i>Blood</i> , 2014, 124, 592-592.	0.6	0
177	Pharmacokinetics of rivaroxaban after bariatric surgery: a case report. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 36, 533-535.	1.0	42
178	Efficacy and safety of thromboprophylaxis with low-molecular-weight heparin or rivaroxaban in hip and knee replacement surgery. <i>Thrombosis and Haemostasis</i> , 2013, 109, 154-163.	1.8	47
179	Increase of Gastrointestinal Bleeding With New Oral Anticoagulants: Problems of a Meta-analysis. <i>Gastroenterology</i> , 2013, 145, 1162-1163.	0.6	8
180	Successful treatment of acute portal vein thrombosis with rivaroxaban. <i>Thrombosis and Haemostasis</i> , 2013, 110, 626-627.	1.8	44

#	ARTICLE	IF	CITATIONS
181	Predictors of deep venous thrombosis in patients admitted to rehabilitation clinics after major orthopaedic surgery. <i>Vasa - European Journal of Vascular Medicine</i> , 2013, 42, 40-49.	0.6	5
182	Acute Treatment Of Pulmonary Embolism With Rivaroxaban - Real Life Data From The Prospective Dresden Noac Registry (NCT01588119). <i>Blood</i> , 2013, 122, 2380-2380.	0.6	5
183	Efficacy and safety of venous thromboembolism prophylaxis with fondaparinux or low molecular weight heparin in a large cohort of consecutive patients undergoing major orthopaedic surgery â€” findings from the ORTHOâ€”EP registry. <i>British Journal of Clinical Pharmacology</i> , 2012, 74, 947-958.	1.1	12
184	Efficacy and safety of venous thromboembolism prophylaxis with apixaban in major orthopedic surgery. <i>Therapeutics and Clinical Risk Management</i> , 2012, 8, 139.	0.9	6
185	Antithrombotic Treatment of Splanchnic Vein Thrombosis: Results of an International Registry. <i>Blood</i> , 2012, 120, 499-499.	0.6	3
186	Safety and Feasibility of a Diagnostic Algorithm Combining Clinical Probability, D-Dimer and Ultrasonography in Suspected Upper Extremity Deep Vein Thrombosis: A Prospective Management Study. <i>Blood</i> , 2012, 120, 391-391.	0.6	2
187	Hospitalization or Outpatient Treatment for Acute Pulmonary Embolism - a Retrospective Cohort Study of 439 Consecutive Patients with Community-Aquired Pulmonary Embolism. <i>Blood</i> , 2012, 120, 3416-3416.	0.6	0
188	Trousseau's syndrome in a patient with adenocarcinoma of unknown primary and therapyâ€”resistant venous thrombosis treated with dabigatran and fondaparinux. <i>British Journal of Clinical Pharmacology</i> , 2011, 72, 715-716.	1.1	10
189	Efficacy and Safety of VTE Prophylaxis with Oral Rivaroxaban Compared to Fondaparinux or Low-Molecular Weight Heparin In a Large Cohort of Consecutive Patients Undergoing Major Orthopaedic Surgery. <i>Blood</i> , 2011, 118, 210-210.	0.6	0
190	Cancer in males and risk of venous thromboembolism. <i>Thrombosis Research</i> , 2010, 125, S155-S159.	0.8	1
191	Safety of venous ultrasound in suspected DVT â€” still a matter of concern?. <i>Thrombosis and Haemostasis</i> , 2009, 102, 5-6.	1.8	21